NOVEL THERAPIES
Cell Therapy
Whether you are looking to commercialise the next autologous or allogeneic cell therapy, CAR-T, or stem, our experienced Process Architects and Engineers will create a best in class design, fit for ‘your process’ development and manufacturing facility enabling you to rapidly bring your cell therapy product to the patients that urgently need these life-changing therapies. Contact us to discuss how we can support your next cell therapy project.
Tell us about your project
and discover how DPS can help you today
Project Profiles
bluebird bio, Clinical Manufacturing Facility
DPS was retained as the design partner to perform the Concept Design for a cGMP clinical manufacturing facility/Pilot Plant for a CAR-T cell therapy product.
Massachusetts
BMS, Cell Therapy Facility
The CAR-T Cell Therapy Facility (CTF) project will be a multi-product facility consisting of 4 production and 2 filling suites with supporting utilities labs, offices and logistic facilities with an overall area of ~20,000m².
Netherlands
ElevateBio, Clinical Manufacturing Facility
DPS was selected to provide professional architectural and engineering services to develop a full design package for ElevateBio’s Massachusetts-based clinical manufacturing facility.
Massachusetts
Lonza Biologics, Multi-product Cell Therapy Manufacturing Suite
Lonza Biologics contracted DPS Group to retrofit an existing manufacturing area to convert the space to a multi-product cell therapy manufacturing suite at its Portsmouth, NH facility.
New Hampshire
Mustang Bio, Cell Processing Facility
DPS Group executed full BOD, Detailed Design and Construction Administration for Mustang Bio’s Cell Processing Facility in Worcester, MA.
Massachusetts
Novartis, Project Next
DPS were engaged to provide the facilities detailed design for Phase 1 of a CAR-T phased manufacturing capacity for Novartis in Stein.
Switzerland
Replimune, Clinical Manufacturing Facility
DPS was hired to provide engineering and design services for a new cGMP manufacturing facility having completed the process definition and test fit phases.
Massachusetts
Sangamo Therapeutics, CAR-Treg Clinical Facility
DPS was engaged to develop a feasibility study to assess the opportunity to retrofit an existing building with a CAR-Treg cell therapy clinical manufacturing facility.
France
Semma Therapeutics, R&D and Clinical Manufacturing Facility
DPS completed the MEP Design for the space to accommodate R&D labs and support areas in Semma’s new Cambridge, MA location.
Massachusetts
Vertex, Gene / Cell Therapy Manufacturing Facility
DPS was engaged to assist Vertex in determining feasibility to build a multi-product, flexible Gene / Cell Therapy Manufacturing facility in Massachusetts.
Massachusetts